The prevalence of attention-deficit/hyperactivity disorder (ADHD) identified in an outpatient sample of 492 adults seeking mental health treatment was nearly 10 times higher than the prevalence identified in epidemiological studies, according to a poster presented at the recent 2018 Annual Meeting of The American Professional Society of ADHD and Related Disorders.
The prevalence of attention-deficit/hyperactivity disorder (ADHD) identified in an outpatient sample of 492 adults seeking mental health treatment was nearly 10 times higher than the prevalence identified in epidemiological studies, according to a poster presented at the recent 2018 Annual Meeting of The American Professional Society of ADHD and Related Disorders (APSARD).
The authors, from the Penn State College of Medicine, wrote that the goal of the study was to examine the prevalence of ADHD in an adult outpatient setting and to examine the unique association between ADHD symptoms and functional impairment, controlling for co-occurring mental health concerns.
Despite the fact that approximately 4% of US adults are diagnosed with ADHD, there have been few studies of its prevalence and associated illness in clinical samples of adults seeking outpatient psychiatric care.
The sample was nearly 70% female and the mean age was 40; patients were starting mental health services. Researchers collected information on the total number of ADHD symptoms using the Adult ADHD Self-Report Scale (ASRS); the average score on the WHO Disability Assessment Schedule 2.0 for overall impairment; and co-occurring psychopathology on the DSM-5 Self-rated Level Cross-Cutting Symptom Measure.
Co-occurring psychopathology screening items included: depression, suicidality, mania, anxiety, sleep problems, and substance abuse. These scores were used as covariates.
ADHD symptoms contributed to the functional impairment of patients with a wide range of psychiatric symptoms. Age, depression, anxiety, substance abuse, mania, and sleep difficulty also explained a significant portion of variance in impairment, while gender and suicidality did not.
Using DSM-IV symptom count criteria (ie, 6+ inattention and/or hyperactivity/impulsivity symptoms), 40.85% of the sample met criteria for ADHD (110 inattentive, 24 hyperactive/impulsive, and 67 combined type). A total of 51.83% met DSM-5 symptom count criteria (125 inattentive presentation, 30 hyperactive/impulsive presentation, and 100 combined presentation).
The authors wrote that the results stress the need for further assessment of ADHD, including diagnostic interview and collateral rating, in standard mental health care for adults.
Reference
Babinski DE, Waxmonsky JG, Bixler EO, et al. Screening for ADHD and impairment in a general outpatient psychiatric sample of adults. Poster presented at the 2018 Annual Meeting of The American Professional Society of ADHD and Related Disorders; Washington, DC; January 12-14, 2018. Poster 32.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More